EU Review Gets Under Way For Curative Vision Loss Gene Therapy
US Filing Of GenSight’s Lumevoq Will Come Later, In H2 2021
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
You may also be interested in...
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.